The Asia Pacific Idiopathic Pulmonary Fibrosis Market would witness market growth of 8.7% CAGR during the forecast period (2021-2027).
Some persons with idiopathic pulmonary fibrosis develop more significant lung illnesses, such as lung cancer, pulmonary emboli (blood clots in the lungs), pneumonia, or excessive blood pressure in the lungs' blood vessels (pulmonary hypertension). The majority of those who are affected, live for 3 to 5 years after being diagnosed. The disease's progress, however, is highly diverse; some people get seriously ill in a matter of months, while others may live with it for a decade or longer.
IPF is a form of lung illness that causes the lungs to scar (fibrosis) for unclear reasons. As time passes, the scarring worsens, making it difficult to take a deep breath and preventing the lungs from receiving adequate oxygen. IPF is a kind of interstitial lung disease that mostly affects the interstitium (the tissue and space around the lungs' air sacs), rather than the airways or blood vessels
In the APAC region, it is discovered that the prevalence of IPF was higher in elderly people than in younger people. In 2020, approximately 30% of patients in Japan, across all age groups, were over the age of 81. As a result, growing geriatric population in various countries of the region would increase the possibilities of lung-related diseases. In addition, IPF prevalence and incidence are obviously higher in older age groups, indicating that aging plays a role in the pathogenesis of IPF. Moreover, IPF appears to be more common in men than in women, however, this could be attributable to sex variations in previous smoking patterns rather than an intrinsic sex-related risk for IPF.
Due to an increase in the number of persons addicted to smoking in the Asia Pacific, the idiopathic pulmonary fibrosis market is predicted to rise significantly over the forecast period. For example, according to World Bank data from 2017, Asia Pacific accounted for almost 30% of all smokers worldwide.
The China market dominated the Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $392.1 million by 2027. The Japan market is poised to grow at a CAGR of 8.1% during (2021 - 2027). Additionally, The India market would experience a CAGR of 9.4% during (2021 - 2027).
Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Idiopathic Pulmonary Fibrosis Market is Projected to reach USD 4.7 Billion by 2027, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 Asia Pacific Idiopathic Pulmonary Fibrosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
Chapter 4. Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 Asia Pacific Pirfenidone Market by Country
4.2 Asia Pacific Nintedanib Market by Country
Chapter 5. Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 Asia Pacific Retail Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country
5.3 Asia Pacific Online Providers Market by Country
Chapter 6. Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country
6.1 China Idiopathic Pulmonary Fibrosis Market
6.1.1 China Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.2 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 Japan Idiopathic Pulmonary Fibrosis Market
6.2.1 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.2 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 India Idiopathic Pulmonary Fibrosis Market
6.3.1 India Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.2 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 South Korea Idiopathic Pulmonary Fibrosis Market
6.4.1 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.2 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.5 Singapore Idiopathic Pulmonary Fibrosis Market
6.5.1 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type
6.5.2 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.6 Malaysia Idiopathic Pulmonary Fibrosis Market
6.6.1 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.6.2 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.7 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market
6.7.1 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type
6.7.2 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Idiopathic Pulmonary Fibrosis Market
TABLE 4 Approvals and Trials – Idiopathic Pulmonary Fibrosis Market
TABLE 5 Acquisition and Mergers – Idiopathic Pulmonary Fibrosis Market
TABLE 6 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 7 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 8 Asia Pacific Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 9 Asia Pacific Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 10 Asia Pacific Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 11 Asia Pacific Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 12 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 13 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 14 Asia Pacific Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 15 Asia Pacific Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 16 Asia Pacific Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 17 Asia Pacific Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 18 Asia Pacific Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 19 Asia Pacific Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 20 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 21 Asia Pacific Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 22 China Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 23 China Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 24 China Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 25 China Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 26 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 27 China Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 28 Japan Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 29 Japan Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 30 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 31 Japan Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 32 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 33 Japan Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 34 India Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 35 India Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 36 India Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 37 India Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 38 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 39 India Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 40 South Korea Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 41 South Korea Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 42 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 43 South Korea Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 44 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 45 South Korea Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 46 Singapore Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 47 Singapore Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 48 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 49 Singapore Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 50 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 Singapore Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 Malaysia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 53 Malaysia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 54 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 55 Malaysia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 56 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 57 Malaysia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 58 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 59 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 60 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 61 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 62 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 63 Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 64 Key Information – GNI Group Ltd.
TABLE 65 Key Information – Shionogi & Co., Ltd.
TABLE 66 Key Information – Mission Therapeutics Ltd.
TABLE 67 Key Information – Galapagos NV
TABLE 68 Key Information – FibroGen, Inc.
TABLE 69 Key Information – AstraZeneca PLC
TABLE 70 key information – F. Hoffmann-La Roche Ltd.
TABLE 71 Key Information – Bristol Myers Squibb Company
TABLE 72 Key Information – Boehringer Ingelheim International GmbH
TABLE 73 Key Information – Biogen, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.